RBC Capital analyst Gregory Renza lowered the price target on Inovio Pharmaceuticals (NASDAQ: INO) to $6.00 (from $7.00) while maintaining ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Analyst Comments Analyst PT Change

Inovio Pharma (INO) Misses Q3 EPS by 89cNovember 14, 2024 5:38 PM Form 8-K INOVIO PHARMACEUTICALS, For: Nov 14November 14, 2024 4:10 PM INOVIO Reports Third Quarter 2024 Financial Results and Recent Business HighlightsNovember 14, 2024 4:05 PM Form 10-Q INOVIO PHARMACEUTICALS, For: Sep 30November 14, 2024 4:03 PM Inovio Pharma (INO) Data Shows INOVIO's INO-3107 Induced Expansion of New Clonal T Cells That Infiltrate Airway Tissue and Correspond With Reduction of Surgeries for RRP PatientsNovember 13, 2024 8:04 AM Immunology Data Shows INOVIO's INO-3107 Induced Expansion of New Clonal T Cells That Infiltrate Airway Tissue and Correspond With Reduction of Surgeries for RRP Patients Observed in Phase 1/2 TrialNovember 13, 2024 8:00 AM